Pluri Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
PLUR$1.12-5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Interim Condensed Consolidated Statements of Operations (Unaudited)
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
U.S. Dollars in thousands (except share and per share data)
| Note | March 31, 2025 | June 30, 2024 | |
|---|---|---|---|
| LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT) | |||
| CURRENT LIABILITIES | |||
| Trade payables | $930 | $964 | |
| Accrued expenses | 1,579 | 1,223 | |
| Operating lease liability | 599 | 559 | |
| Accrued vacation and recuperation | 756 | 702 | |
| Warrant liability | 263 | - | |
| Advances from customers | 333 | 43 | |
| Other accounts payable | 1,245 | 963 | |
| Total current liabilities | 5,705 | 4,454 | |
| LONG-TERM LIABILITIES | |||
| Accrued severance pay | 631 | 605 | |
| Operating lease liability | 5,640 | 5,026 | |
| Loan from the European Investment Bank (“EIB”) | 4 | 24,948 | 24,027 |
| Total long-term liabilities | 31,219 | 29,658 | |
| COMMITMENTS AND CONTINGENCIES | 3 | ||
| SHAREHOLDERS’ EQUITY (DEFICIT) | |||
| Share capital: | 5 | ||
| Common shares, $0.00001 par value per share: Authorized: 37,500,000 as of March 31, 2025, and June 30, 2024; Issued and outstanding: 7,775,443 and 5,408,212 shares as of March 31, 2025, and June 30, 2024, respectively | * | * | |
| Additional paid-in capital | 430,983 | 420,568 | |
| Accumulated deficit | (435,457) | (420,472) | |
| Total shareholders’ equity (deficit) | (4,474) | 96 | |
| Non-controlling interests | 4,957 | 5,319 | |
| Total equity | 483 | 5,415 | |
| Total liabilities and equity | $37,407 | $39,527 | |
| (*) | Less than $1 |
|---|
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
U.S. Dollars in thousands (except share and per share data)
| Nine months ended March 31, · Three months ended March 31, | |||||
|---|---|---|---|---|---|
| Note | 2025 | 2024 | 2025 | 2024 | |
| Revenues | $938 | $230 | $427 | $71 | |
| Cost of revenues | (491) | - | (291) | - | |
| Gross profit | 447 | 230 | 136 | 71 | |
| Operating expenses: | |||||
| Research and development expenses | $(9,797) | $(10,066) | $(3,235) | $(3,362) | |
| Less: participation by the National Institute of Allergy and Infectious Diseases (“NIAID”), the Israeli Innovation Authority (“IIA”), Horizon Europe | 940 | 1,015 | 192 | 268 | |
| Research and development expenses, net | (8,857) | (9,051) | (3,043) | (3,094) | |
| General and administrative expenses | (7,145) | (7,303) | (2,493) | (2,511) | |
| Operating loss | (15,555) | (16,124) | (5,400) | (5,534) | |
| Other financial income (expenses), net | 7 | 714 | 1,290 | (723) | 362 |
| Interest expenses | (640) | (648) | (212) | (218) | |
| Total financial income (expenses), net | 74 | 642 | (935) | 144 | |
| Net loss | $(15,481) | $(15,482) | $(6,335) | $(5,390) | |
| Net loss attributed to non-controlling interest | $(496) | $(323) | $(188) | $(97) | |
| Net loss attributed to shareholders | $(14,985) | $(15,159) | $(6,147) | $(5,293) | |
| Loss per share: | |||||
| Basic and diluted net loss per share | $(2.56) | $(2.92) | $(0.94) | $(1.01) | |
| Weighted average number of shares used in computing basic and diluted net loss per share | 5,857,743 | 5,193,808 | 6,563,555 | 5,221,162 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.